| Rank |
Pathway / Axis |
Cancer / Tumor Context |
Normal Tissue Context |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Mitochondrial ETC Complex I inhibition → ATP depletion (acetogenins) |
Complex I ↓; ATP ↓; energetic crisis ↑ |
Risk of toxicity with sufficient exposure |
P, R, G |
Metabolic choke-point |
Core mechanistic theme: annonaceous acetogenins inhibit mitochondrial complex I, suppressing ATP generation (often framed as a basis for cytotoxicity in vitro). |
| 2 |
ROS / mitochondrial stress (secondary to Complex I inhibition) |
ROS ↑ or redox destabilization (context); oxidative damage ↑ |
Oxidative injury risk depends on exposure |
P, R, G |
Stress amplification |
ROS direction varies by model/extract; best treated as secondary to energy failure rather than a universal primary ROS driver. |
| 3 |
Intrinsic apoptosis (mitochondrial; caspases; PARP) |
Apoptosis ↑; caspase activation ↑; cl-PARP ↑ (reported) |
↔ / toxicity risk at higher exposures |
G |
Cell death execution |
Common endpoint in cancer cell studies; often downstream of energetic collapse and stress signaling. |
| 4 |
Cell-cycle control / proliferation |
Proliferation ↓; cell-cycle arrest ↑ (reported; phase varies) |
↔ |
G |
Cytostasis |
Frequently reported phenotype-level effect across models; checkpoint phase depends on tumor type and extract composition. |
| 5 |
NF-κB inflammatory transcription |
NF-κB ↓; pro-inflammatory/survival outputs ↓ (reported) |
Anti-inflammatory effects reported |
R, G |
Anti-inflammatory / anti-survival transcription |
Many extracts/constituents are reported to reduce NF-κB signaling, contributing to reduced cytokines and survival programs. |
| 6 |
PI3K → AKT (± mTOR) and other survival kinases |
Survival kinase tone ↓ (reported; model-dependent) |
↔ |
R, G |
Growth/survival suppression |
Often listed in reviews; keep “reported/model-dependent” because extracts vary substantially. |
| 7 |
MAPK re-wiring (ERK / JNK / p38) |
Stress-MAPK modulation (context-dependent) |
↔ |
P, R, G |
Signal reprogramming |
MAPK directions are heterogeneous across studies; avoid fixed arrows unless tied to a specific paper/extract. |
| 8 |
Invasion / metastasis programs (MMPs / EMT) |
Migration/invasion ↓; MMPs/EMT markers ↓ (reported) |
↔ |
G |
Anti-invasive phenotype |
Downstream phenotype-level outcomes reported in some tumor systems; not universal. |
| 9 |
Angiogenesis signaling (VEGF & related outputs) |
VEGF/angiogenic outputs ↓ (reported) |
↔ |
G |
Anti-angiogenic support |
Usually observed as later gene-expression/assay outcomes, often linked to NF-κB and survival-pathway suppression. |
| 10 |
Safety constraint: neurotoxicity signal (annonacin; atypical parkinsonism association) |
— |
Long-term/high exposure concern: neurotoxicity & atypical parkinsonism association reported |
— |
Translation constraint |
Evidence links Annonaceae consumption (including soursop) with atypical parkinsonism in the French Caribbean; annonacin crosses BBB in animal studies and causes ATP depletion and neurodegenerative patterns with chronic exposure. |